OTCMKTS:OMBP - Omni Bio Pharmaceutical Stock Price, News & Analysis

$0.01
0.00 (0.00 %)
(As of 08/21/2019 04:00 PM ET)
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.01
MA: $0.01
$0.02
52-Week Range
$0.0085
Now: $0.01
$0.0386
VolumeN/A
Average Volume1,000 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OMBP
CUSIPN/A
Phone970-237-5178

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1
Next Earnings DateN/A
OptionableNot Optionable

Receive OMBP News and Ratings via Email

Sign-up to receive the latest news and ratings for OMBP and its competitors with MarketBeat's FREE daily newsletter.


Omni Bio Pharmaceutical (OTCMKTS:OMBP) Frequently Asked Questions

What is Omni Bio Pharmaceutical's stock symbol?

Omni Bio Pharmaceutical trades on the OTCMKTS under the ticker symbol "OMBP."

Has Omni Bio Pharmaceutical been receiving favorable news coverage?

Media headlines about OMBP stock have been trending positive recently, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Omni Bio Pharmaceutical earned a news impact score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term. View News Stories for Omni Bio Pharmaceutical.

Who are some of Omni Bio Pharmaceutical's key competitors?

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), Flexion Therapeutics (FLXN), Biocept (BIOC), Acorda Therapeutics (ACOR) and Gemini (GKX).

Who are Omni Bio Pharmaceutical's key executives?

Omni Bio Pharmaceutical's management team includes the folowing people:
  • Dr. Leland Shapiro M.D., Principal Investigator for Viral & Bacterial Disorders

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omni Bio Pharmaceutical's stock price today?

One share of OMBP stock can currently be purchased for approximately $0.01.

What is Omni Bio Pharmaceutical's official website?

The official website for Omni Bio Pharmaceutical is http://www.omnibiopharma.com/.

How can I contact Omni Bio Pharmaceutical?

Omni Bio Pharmaceutical's mailing address is 181 W BOARDWALK DRIVE SUITE 202, FORT COLLINS CO, 80525. The biopharmaceutical company can be reached via phone at 970-237-5178 or via email at [email protected]


MarketBeat Community Rating for Omni Bio Pharmaceutical (OTCMKTS OMBP)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Omni Bio Pharmaceutical and other stocks. Vote "Outperform" if you believe OMBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel